Qin ZQ, Yang SF, Chen Y, Hong CJ, Zhao TW, Yuan GR, Yang L, Gao L, Wang X, Lu LQ. Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer. World J Clin Cases 2022; 10(4): 1164-1171 [PMID: 35211549 DOI: 10.12998/wjcc.v10.i4.1164]
Corresponding Author of This Article
Li-Qin Lu, MD, Professor, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), No. 158 Shangtang Road, Xiacheng District, Hangzhou 310014, Zhejiang Province, China. llq199@outlook.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 6, 2022; 10(4): 1164-1171 Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1164
Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer
Zhi-Quan Qin, Si-Fu Yang, Yun Chen, Chao-Jin Hong, Tong-Wei Zhao, Guo-Rong Yuan, Liu Yang, Liang Gao, Xiao Wang, Li-Qin Lu
Zhi-Quan Qin, Si-Fu Yang, Yun Chen, Chao-Jin Hong, Tong-Wei Zhao, Guo-Rong Yuan, Liu Yang, Liang Gao, Xiao Wang, Li-Qin Lu, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China
Author contributions: Qin ZQ and Yang SF designed and performed the research and wrote the paper; Chen Y, Hong CJ and Zhao TW designed the research and supervised the report; Yuan GR and Yang L designed the research and contributed to the analysis; Gao L and Wang X provided clinical advice; Lu LQ supervised the report; all authors gave final approval for the version to be submitted.
Institutional review board statement: This study was reviewed and approved by the ethics committee of Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College) (2021QT290).
Informed consent statement: The ethics committee of Zhejiang Provincial People's Hospital (People's Hospital of Hangzhou Medical College) waived the requirement for written informed patient consent, because this was a retrospective analysis based on the assessment of medical records.
Conflict-of-interest statement: The authors declared no conflicts of interest for this manuscript.
Data sharing statement: No additional data were available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Qin Lu, MD, Professor, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), No. 158 Shangtang Road, Xiacheng District, Hangzhou 310014, Zhejiang Province, China. llq199@outlook.com
Received: September 15, 2021 Peer-review started: September 15, 2021 First decision: October 18, 2021 Revised: October 27, 2021 Accepted: December 22, 2021 Article in press: December 22, 2021 Published online: February 6, 2022 Processing time: 130 Days and 20.5 Hours
ARTICLE HIGHLIGHTS
Research background
To date, current available treatment options for non-small cell lung cancer (NSCLC) are associated with significant limitations in safety and efficacy. Therefore, development and achievement of potential therapeutic therapies for NSCLC is necessary.
Research motivation
This study mainly evaluated the efficacy and safety of continuous intravenous infusion of recombinant human endostatin (Rh-endostain) using an infusion pump in patients with retreated advanced NSCLC.
Research objectives
This study aimed to investigate the efficacy and safety of continuous intravenous infusion of Rh-endostain in retreated advanced NSCLC patients.
Research methods
Forty-five patients from Zhejiang Provincial People's Hospital received continuous intravenous infusion of Rh-endostain using an infusion pump. Objective response rate (ORR), clinical benefit rate (CBR), median progression-free survival (mPFS), and adverse events were analyzed after treatment.
Research results
In these 45 patients, ORR was 22.2%, CBR was 84.4%, and mPFS was 5.3 mo. The following AEs were observed as follows, decreased hemoglobin (34 cases, 75.6%), nausea/vomiting (32 cases, 71.1%), elevated transaminase (24 cases, 53.3%), leukopenia (16 cases, 35.6%), thrombocytopenia (14 cases, 31.1%), and constipation (1 case, 3.4%). None of the patients had leukopenia, nausea/vomiting, and constipation of grade III and above.
Research conclusions
Five-day continuous intravenous infusion of Rh-endostain using an infusion pump improved patient adherence, and brought about favorable efficacy and safety in retreated advanced NSCLC.
Research perspectives
Prospective clinical randomized controlled trials will be conducted for further validation of the efficacy and safety of continuous intravenous infusion of Rh-endostatin combined with chemotherapy in retreated advanced NSCLC.
